Augusta University
Sejong Bae, PhD
Chair, Department of Biostatistics, Data Science, and Epidemiology, School of Public Health
- Augusta GA UNITED STATES
- EB203
- Biostatistics, Data Science, & Epidemiology
Dr. Bae's research interests encompass disease, health equity, clinical trials, and advanced biostatistics methods
Contact More Open optionsMultimedia
Social
Biography
Sejong Bae, PhD, is a distinguished biostatistician and researcher with over two decades of experience in clinical, translational, and population-based research. Dr. Bae is the inaugural chair of the Department of Biostatistics, Data Science, and Epidemiology at Augusta University's School of Public Health. Dr. Bae's expertise spans biostatistics, data science, and epidemiology, with a focus on clinical trials, biomarkers, and health equity.
He has held significant academic and leadership positions, notably at the University of Alabama at Birmingham (UAB), where he served as a Professor of Medicine and led the Biostatistics & Bioinformatics Shared Facility at the O'Neal Comprehensive Cancer Center. Dr. Bae has an extensive publication record, contributing to over 230 peer-reviewed manuscripts in high-impact journals, including JAMA and Cancer Letters. His research interests encompass cancer, cardiovascular diseases, health equity, clinical trials, and advance biostatistics methods. His work has been cited over 10,000 times, reflecting his significant impact in the field.
Areas of Expertise
Education
University of Alabama at Birmingham
PhD
Biostatistics
1999University of Georgia
Master of Science
Statistics
1993University of Georgia
Bachelor's
Computer Science
1990Affiliations
- The Society of Hematologic Oncology
- American Society of Clinical Oncology
- American Association for Cancer Research
- American Statistical Association
- International Statistical Institute
- American Public Health Association
- International Biometric Society
- Modelling and Simulation Society of Australia and New Zealand
Links
Media Appearances
Chair named for Department of Biostatistics, Data Science, and Epidemiology
Augusta University News online
2025-03-31
Teresa Waters, PhD, dean of Augusta University’s School of Public Health, has announced the addition of Sejong Bae, PhD, as the inaugural chair of the Department of Biostatistics, Data Science, and Epidemiology.
Articles
Elevated CCL20 and IL-10 enhance 5-fluorouracil tolerance in colon cancer
Biomedicine & Pharmacotherapy2025-08-01
Conventional chemotherapeutics for colon cancer often fail to achieve optimal clinical outcomes, as many patients develop resistance and experience significant toxicity, thereby increasing the overall health burden. Understanding the mechanisms conferring resilience to cancer cells is essential for developing more effective therapies. 5-Flourouracil (5FU) is the standard of care used for colon cancer.
Association of Race With Risk of Incident Cardiovascular Disease, Coronary Heart Disease, Heart Failure, and Stroke
JACC: Advances2025-06-01
In prior studies of cumulative risk factor exposure, self-identified race was independently associated with incident cardiovascular disease (CVD). A recent study suggests clinical, demographic, and socioeconomic factors explain racial differences. We used propensity score matching to study race as an independent incident CVD risk factor.
YIA25-001: Molecular Residual Disease (MRD) Guided Adjuvant Therapy In Renal Cell Carcinoma (RCC) - The MRD GATE RCC Study
Journal of the National Comprehensive Cancer Network2025-03-28
Ultrasensitive ctDNA assays are emerging as a prognostic marker in various tumor types including in renal cell carcinoma (RCC). Pembrolizumab is currently approved for intermediate and high-risk, surgically resected RCC patients based on a survival benefit of approximately 5% at 48 months. There are no currently established biomarkers for treatment selection. We examine a tumor informed MRD-guided approach to the assignment of adjuvant immunotherapy in an ambispective cohort.
ADT-1004: a first-in-class, oral pan-RAS inhibitor with robust antitumor activity in preclinical models of pancreatic ductal adenocarcinoma
Molecular cancer2025-03-13
Oncogenic KRAS mutations occur in nearly, 90% of patients with pancreatic ductal adenocarcinoma (PDAC). Targeting KRAS has been complicated by mutational heterogeneity and rapid resistance. We developed a novel pan-RAS inhibitor, ADT-1004 (an oral prodrug of ADT-007) and evaluated antitumor activity in murine and human PDAC models.
Cancer-related health behaviors during the COVID 19 pandemic in geographically diverse samples across the US
BMC cancer2025-01-09
The COVID-19 pandemic involved business closures (e.g., gyms), social distancing policies, and prolonged stressful situations that may have impacted engagement in health behaviors. Our study assessed changes in cancer-related health behaviors during the pandemic, specifically physical activity, fruit/vegetable intake, smoking/tobacco use, and alcohol consumption.
